礼来(LLY.N)公布关于Orforglipron的第二项肥胖试验结果，药物使肥胖和糖尿病患者的体重减轻了9.6%，计划在2025年申请减肥药的批准。

Disclaimer:

1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.

2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.